Aboubacar Alassane Oumar1,2, Yacouba Cissoko1,3, Issa Konaté1,3, Adam Kane1, Jean Paul Dembélé1,3, Mamadou Cissé4, Robert Leo Murphy5, Jean Cyr Yombi6, Moussa Seydi7, Sounkalo Dao1,2,3, Mamoudou Maiga1,2,5. 1. Université des Sciences, des Techniques et des Technologies de Bamako, Bamako, Mali. 2. Centre de Formation et de Recherche sur le VIH et la Tuberculose, Bamako, Mali. 3. CHU Point G, Service de Maladies infectieuses, Bamako, Mali. 4. Centre d'Ecoute, de Soins, d'Animation et de Conseil, Bamako, Mali. 5. Northwestern University, Chicago, IL, USA. 6. Université catholique de Louvain, AIDS référence Centre, Bruxelles, Belgique. 7. Université Cheikh Anta Diop, Dakar, Sénégal.
Abstract
BACKGROUND: HIV-2 leads to a less-severe disease than HIV-1 but is known to be resistant to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). We goaled to evaluate the clinical and biological outcomes of HIV-1 and HIV-2 infected-patients under Antiretroviral Therapy (ART) that do not include NNRTIs. METHODS: This is a case-control study of 100 participants (half in each group) to measure the frequency of clinical and biological adverse effects, and disease outcome at 6 and 12 months of treatment (M6 and M12) We included. RESULTS: Opportunistic infections were more frequent in HIV-1 infected patients with 82% when compared to HIV-2, 68%. However, the prevalence of treatment adverse events was slightly higher in HIV-2 infected patients. The average increase of CD4 cell count at M6 of treatment was 139.93 and 159.41 cells/mm3, for HIV-2 and HIV-1 groups respectively, and at 153 and 217 cells/mm3, at M12 for HIV-2 and HIV-1 respectively. A total of nine HIV-2 and six HIV-1 deaths were reported during the study. CONCLUSION: This study has shown that ART regimens that do not include NNRTIs are effective equally in the treatment of HIV-1 and HIV-2 infections. Nevertheless, we recommend regular and continuous laboratory monitoring for all HIV treated patients.
BACKGROUND: HIV-2 leads to a less-severe disease than HIV-1 but is known to be resistant to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). We goaled to evaluate the clinical and biological outcomes of HIV-1 and HIV-2 infected-patients under Antiretroviral Therapy (ART) that do not include NNRTIs. METHODS: This is a case-control study of 100 participants (half in each group) to measure the frequency of clinical and biological adverse effects, and disease outcome at 6 and 12 months of treatment (M6 and M12) We included. RESULTS: Opportunistic infections were more frequent in HIV-1 infected patients with 82% when compared to HIV-2, 68%. However, the prevalence of treatment adverse events was slightly higher in HIV-2 infected patients. The average increase of CD4 cell count at M6 of treatment was 139.93 and 159.41 cells/mm3, for HIV-2 and HIV-1 groups respectively, and at 153 and 217 cells/mm3, at M12 for HIV-2 and HIV-1 respectively. A total of nine HIV-2 and six HIV-1 deaths were reported during the study. CONCLUSION: This study has shown that ART regimens that do not include NNRTIs are effective equally in the treatment of HIV-1 and HIV-2 infections. Nevertheless, we recommend regular and continuous laboratory monitoring for all HIV treated patients.
Entities:
Keywords:
ART; Adverse Effects Taxonomy Topics; HIV-1; HIV-2; Mali
Authors: N A Smith; T Shaw; N Berry; C Vella; L Okorafor; D Taylor; J Ainsworth; A Choudhury; R S Daniels; S El-Gadi; A Fakoya; G Moyle; J Oxford; R Tedder; S O'Shea; A de Ruiter; J Breuer Journal: J Infect Date: 2001-02 Impact factor: 6.072
Authors: C T Ndour; G Batista; N M Manga; N F Ngom Guèye; N M Dia Badiane; L Fortez; P S Sow Journal: Med Mal Infect Date: 2006-02-15 Impact factor: 2.152